CompletedPhase 2

Protocol for Women at Increased Risk of Developing Breast Cancer

United States72 participantsStarted 2003-04

Plain-language summary

To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * women who have a high risk of breast cancer * older than 18 years Exclusion Criteria: * anticoagulants * marked breast tenderness * pregnant or within twelve months of breast feeding/childbirth

What they're measuring

Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67

Timeframe: Baseline and 12 months

Trial details

NCT IDNCT00291694

SponsorCarol Fabian, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-12

Results submitted2013-06-24

View on ClinicalTrials.gov More Breast Cancer trials